Clinical Trials Logo

Diabetic Nephropathy clinical trials

View clinical trials related to Diabetic Nephropathy.

Filter by:

NCT ID: NCT04562025 Recruiting - Clinical trials for Diabetic Nephropathy

Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy

UC-MSCs
Start date: September 25, 2020
Phase: N/A
Study type: Interventional

Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. DN is a refractory disease with low awareness, high incidence, and high disability. The incidence of DN can reach 30 to 40% after 20 years of diabetes, of which 5~10% of patients will progress to end-stage renal disease, and epidemiological surveys predict that by 2030, DN will become the seventh leading cause of death in the world. Currently, there are no effective drugs for treating DN. This clinical trial is to inspect the safety and efficiency of human umbilical cord mesenchymal stem cells (UC-MSCs) therapy for patients with DN.

NCT ID: NCT04127084 Recruiting - Type 2 Diabetes Clinical Trials

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Start date: October 15, 2019
Phase: Phase 4
Study type: Interventional

Diabetic kidney disease has become the leading cause for ESRD worldwide.Albuminuria is a major risk factor for progression of diabetic nephropathy. SGLT2 inhibitors are the first antiglycaemic drugs with direct renoprotection, which are thought to protect the kidneys by lowering albuminuria, stimulating urinary glucose excretion ,reducing systemic blood pressure, while simultaneously improving multiple other risk factors in a glucose-independent manner. However, the precise mechanisms behind the renal beneficial effect of SGLT2 inhibitors are not entirely elucidated, although ongoing outcome trials will confirm these findings. This study is to assess the impact of three months of treatment with SGLT2 Inhibitions on different levels of albuminuria in patients with type 2 diabetes and to evaluate the effects of SGLT2 inhibition treatment on markers for podocyte damage , renal fibrosis, inflammation,oxidative stress and renin-angiotensin- aldosterone system.

NCT ID: NCT04125329 Recruiting - Clinical trials for Diabetic Nephropathy

Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy

Start date: April 1, 2020
Phase: Early Phase 1
Study type: Interventional

This clinical trial assessed the safety of human umbilical cord mesenchymal stem cell therapy in 15 patients with diabetic nephropathy. Fifteen subjects received umbilical cord mesenchymal stem cell therapy 3 times. Approximately 1 × 106/kg of human umbilical cord mesenchymal stem cells were administered by peripheral intravenous infusion once a month .Endpoints:Primary endpoint: Safety and adverse events (safety and tolerability of umbilical cord mesenchymal stem cell therapy within 60 weeks).Secondary endpoint indicators:Efficacy measures: eGFR, urinary albumin-to-creatinine ratio, and percentage changes of 24-h urinary protein quantities from baseline to 60 weeks.

NCT ID: NCT04027530 Completed - Clinical trials for Type 2 Diabetes Mellitus

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

ROCKIES
Start date: December 10, 2020
Phase: Phase 4
Study type: Interventional

Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate. Moreover, this research will focus on the effects of sodium-glucose cotransporter 2 inhibition on renal tissue oxygenation and oxygen consumption as well as a change in intrarenal hemodynamics and perfusion, and a shift of fuel metabolites. Elucidation the mechanisms underlying the effects of SGLT2 inhibition will advance our knowledge and contribute to their optimal clinical utilization in the treatment of chronic kidney disease in diabetes and possibly beyond.

NCT ID: NCT03804879 Completed - Clinical trials for Diabetic Nephropathy

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

Start date: December 17, 2018
Phase: Phase 2
Study type: Interventional

Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (SoC) (angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)). This non-confirmatory Phase 2 study was designed to determine the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of nidufexor in combination with ACEI or ARB at a dose level that is SoC as judged by the study doctor in patients with type 2 diabetes and nephropathy.

NCT ID: NCT03658317 Not yet recruiting - Clinical trials for Diabetic Nephropathy

Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy

Start date: September 2018
Phase: N/A
Study type: Interventional

diabetic nephropathy is one of the leading causes of end stage renal disease

NCT ID: NCT03436693 Completed - Clinical trials for Diabetic Nephropathy

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Start date: February 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo

NCT ID: NCT03413215 Recruiting - Hypertension Clinical Trials

Effects of Multidisciplinary Intensive Targeted Care in Improving Diabetes Outcomes: a Pilot Study in Singapore

IDEALS
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This study aims to investigate whether channeling purposefully structured resources to patients at high risk of developing diabetic complications to interdisciplinary team clinic consultations, interspersed with closer remote follow-up and aided by simple technology will be more effective than usual care in controlling diabetes mellitus, controlling multiple cardiovascular risk factors and reducing clinical event rates.

NCT ID: NCT03407989 Active, not recruiting - Clinical trials for Diabetic Nephropathy

SWIDINEP a Swiss Diabetic Nephropathy Cohort

SWIDINEP
Start date: January 1, 2014
Phase:
Study type: Observational

With our SWIDINEP cohort, we propose to explore the relationship between vascular risk markers and renal function decline in CKD stage 1-5. In order to realize these goals, we intend to recruit 200 patients within a 7y recruitment period (2014-2021). Recruitment is done in the nephrology and diabetes ambulatory clinics in the CHUV at Lausanne. Each eligible patient is identified and whether he/she can be proposed the study is discussed with the physician in charge of the patient. Once the patient is informed and has signed the consent form, he/she is examined in the Service of Nephrology at baseline, 2y and 5y.

NCT ID: NCT02928250 Completed - Type 1 Diabetes Clinical Trials

Role of Carnosine as an Adjuvant Therapy for Diabetic Nephropathy in Pediatrics With Type 1 Diabetes

Start date: August 2015
Phase: N/A
Study type: Interventional

Carnosine, a naturally-occurring dipeptide (β-alanyl-L-histidine) first described in 1900 by Gulewitsch and Amiradzibi, is found predominantly in post-mitotic tissues (e.g. brain and innervated muscle) of vertebrates . Carnosine is claimed to decrease oxygen free-radical mediated damage to cellular macromolecules either by chelating divalent cations or scavenging hydroxy radicals with its imidazole moiety. Free-radical damage is not the only process to affect the structure of proteins and nucleic acids. To the best of our knowledge, no previous study assessed the role of carnosine in diabetes associated complications in particular diabetic nephropathy and there is insufficient evidence to recommend its supplementation in those patients. Therefore, this study was undertaken to investigate the role of carnosine as an adjuvant therapy for diabetic nephropathy in children and adolescents with type 1 diabetes and assess its relation to microalbuminuria, tubulointerstitial damage marker, glycemic control and oxidative stress.